Linmarie Sikich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Linmarie Sikich has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Cheryl Alderman
Department of Psychiatry and Behavioral Sciences Duke University School of Medicine Durham North Carolina USA
3 shared publications- Jeremy Veenstra-VanderWeele
Columbia University
3 shared publications - Misha Eliasziw
Department of Public Health and Community Medicine, Tufts University, Boston, MA 02111, USA
3 shared publications - Tara Chandrasekhar
M.J. Cullen is senior director of assessment, evaluation, and research for graduate medical education, University of Minnesota Medical School, Minneapolis, Minnesota; ORCID: https://orcid.org/
3 shared publications Abby Scheer
Department of Psychiatry and Behavioral Sciences Duke University School of Medicine Durham North Carolina USA
2 shared publicationsAlicia Montgomery
Department of Psychiatry Columbia University New York New York USA
2 shared publications
Latest Publications
- Open Access
- 10 October 2025
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- p. 1-7
Evaluation of a 5-Item Subset of the Social Responsiveness Scale for Distinguishing Between Children With and Without Autism Spectrum Disorder
Purpose: Identifying children with autism spectrum disorder (ASD) of all ages using a screening tool is valuable. We evaluated a shortened version of the 65-item Social Responsiveness Scale (SRS). Methods: A total of 1,462 dyads from the Simons Simplex Collection consisted of a child with a clinically confirmed diagnosis of ASD and a sibling without ASD. All siblings were free of suspected intellectual disabilities and severe learning disabilities, had neither developmental nor psychiatric disorders, and did not have an Individual Education Plan for extensive special education services. Areas under Receiver Operating Characteristics (AUROC) curves quantified scale performance. A non-inferiority margin of − 0.005 was pre-specified. Results: The AUROC for the 5-item scale (5iSRS) was 0.9943, the predictive value positive was 97.3% and predictive value negative was 96.9%. The AUROC for the 65-item SRS was 0.9926, resulting in an AUROC difference of 0.0017 (95% CI=[– 0.0003, 0.0037]) and meeting the non-inferiority criterion. Conclusion: The 5iSRS can distinguish between children with and without ASD and is non-inferior to the 65-item SRS, and thus may have substantial utility in research, community, and clinical settings. Given that this initial evaluation of the shortened version was performed among children in simplex families with selected unaffected siblings, further evaluations in community and clinical settings among non-related children with varying levels of autistic traits and/or other behavioral challenges are needed prior to considering the shortened version as a viable ASD screening tool.
- 10 October 2025
- Published by Springer Nature in Journal of Autism and Developmental Disorders
- p. 1-7
Open AccessEvaluation of a 5-Item Subset of the Social Responsiveness Scale for Distinguishing Between Children With and Without Autism Spectrum Disorder
Purpose: Identifying children with autism spectrum disorder (ASD) of all ages using a screening tool is valuable. We evaluated a shortened version of the 65-item Social Responsiveness Scale (SRS). Methods: A total of 1,462 dyads from the Simons Simplex Collection consisted of a child with a clinically confirmed diagnosis of ASD and a sibling without ASD. All siblings were free of suspected intellectual disabilities and severe learning disabilities, had neither developmental nor psychiatric disorders, and did not have an Individual Education Plan for extensive special education services. Areas under Receiver Operating Characteristics (AUROC) curves quantified scale performance. A non-inferiority margin of − 0.005 was pre-specified. Results: The AUROC for the 5-item scale (5iSRS) was 0.9943, the predictive value positive was 97.3% and predictive value negative was 96.9%. The AUROC for the 65-item SRS was 0.9926, resulting in an AUROC difference of 0.0017 (95% CI=[– 0.0003, 0.0037]) and meeting the non-inferiority criterion. Conclusion: The 5iSRS can distinguish between children with and without ASD and is non-inferior to the 65-item SRS, and thus may have substantial utility in research, community, and clinical settings. Given that this initial evaluation of the shortened version was performed among children in simplex families with selected unaffected siblings, further evaluations in community and clinical settings among non-related children with varying levels of autistic traits and/or other behavioral challenges are needed prior to considering the shortened version as a viable ASD screening tool.
- Open Access
- 7 January 2023
- Published by Wiley in Autism Research
- Vol. 16 (3) , 502-523
Genetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder
Oxytocin (OT), the brain's most abundant neuropeptide, plays an important role in social salience and motivation. Clinical trials of the efficacy of OT in autism spectrum disorder (ASD) have reported mixed results due in part to ASD's complex etiology. We investigated whether genetic and epigenetic variation contribute to variable endogenous OT levels that modulate sensitivity to OT therapy. To carry out this analysis, we integrated genome‐wide profiles of DNA‐methylation, transcriptional activity, and genetic variation with plasma OT levels in 290 participants with ASD enrolled in a randomized controlled trial of OT. Our analysis identified genetic variants with novel association with plasma OT, several of which reside in known ASD risk genes. We also show subtle but statistically significant association of plasma OT levels with peripheral transcriptional activity and DNA‐methylation profiles across several annotated gene sets. These findings broaden our understanding of the effects of the peripheral oxytocin system and provide novel genetic candidates for future studies to decode the complex etiology of ASD and its interaction with OT signaling and OT‐based interventions.Lay Summary: Oxytocin (OT) is an abundant chemical produced by neurons that plays an important role in social interaction and motivation. We investigated whether genetic and epigenetic factors contribute to variable OT levels in the blood. To this, we integrated genetic, gene expression, and non‐DNA regulated (epigenetic) signatures with blood OT levels in 290 participants with autism enrolled in an OT clinical trial. We identified genetic association with plasma OT, several of which reside in known autism risk genes. We also show statistically significant association of plasma OT levels with gene expression and epigenetic across several gene pathways. These findings broaden our understanding of the factors that influence OT levels in the blood for future studies to decode the complex presentation of autism and its interaction with OT and OT‐based treatment.
- 7 January 2023
- Published by Wiley in Autism Research
- Vol. 16 (3) , 502-523
Open AccessGenetic and epigenetic signatures associated with plasma oxytocin levels in children and adolescents with autism spectrum disorder
Oxytocin (OT), the brain's most abundant neuropeptide, plays an important role in social salience and motivation. Clinical trials of the efficacy of OT in autism spectrum disorder (ASD) have reported mixed results due in part to ASD's complex etiology. We investigated whether genetic and epigenetic variation contribute to variable endogenous OT levels that modulate sensitivity to OT therapy. To carry out this analysis, we integrated genome‐wide profiles of DNA‐methylation, transcriptional activity, and genetic variation with plasma OT levels in 290 participants with ASD enrolled in a randomized controlled trial of OT. Our analysis identified genetic variants with novel association with plasma OT, several of which reside in known ASD risk genes. We also show subtle but statistically significant association of plasma OT levels with peripheral transcriptional activity and DNA‐methylation profiles across several annotated gene sets. These findings broaden our understanding of the effects of the peripheral oxytocin system and provide novel genetic candidates for future studies to decode the complex etiology of ASD and its interaction with OT signaling and OT‐based interventions.Lay Summary: Oxytocin (OT) is an abundant chemical produced by neurons that plays an important role in social interaction and motivation. We investigated whether genetic and epigenetic factors contribute to variable OT levels in the blood. To this, we integrated genetic, gene expression, and non‐DNA regulated (epigenetic) signatures with blood OT levels in 290 participants with autism enrolled in an OT clinical trial. We identified genetic association with plasma OT, several of which reside in known autism risk genes. We also show statistically significant association of plasma OT levels with gene expression and epigenetic across several gene pathways. These findings broaden our understanding of the factors that influence OT levels in the blood for future studies to decode the complex presentation of autism and its interaction with OT and OT‐based treatment.
- 12 December 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 62 (4) , 427-434
An Optimized Version of the Positive and Negative Symptoms Scale (PANSS) for Pediatric Trials
- 12 December 2022
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 62 (4) , 427-434
An Optimized Version of the Positive and Negative Symptoms Scale (PANSS) for Pediatric Trials
- Open Access
- 11 June 2022
- Published by Springer Nature in Molecular Autism
- Vol. 13 (1) , 1-11
Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program
Background: Autism spectrum disorder (ASD) is a common and heterogeneous neurodevelopmental condition that is characterized by the core symptoms of social communication difficulties and restricted and repetitive behaviors. At present, there is an unmet medical need for therapies to ameliorate these core symptoms in order to improve quality of life of autistic individuals. However, several challenges are currently faced by the ASD community relating to the development of pharmacotherapies, namely in the conduct of clinical trials. Balovaptan is a V1a receptor antagonist that has been investigated to improve social communication difficulties in individuals with ASD. In this viewpoint, we draw upon our recent first-hand experiences of the balovaptan clinical development program to describe current challenges of ASD trials. Discussion points: The balovaptan trials were conducted in a wide age range of individuals with ASD with the added complexities associated with international trials. When summarizing all three randomized trials of balovaptan, a placebo response was observed across several outcome measures. Placebo response was predicted by greater baseline symptom severity, online recruitment of participants, and less experienced or non-academic trial sites. We also highlight challenges relating to selection of outcome measures in ASD, the impact of baseline characteristics, and the role of expectation bias in influencing trial results. Conclusion: Taken together, the balovaptan clinical development program has advanced our understanding of the key challenges facing ASD treatment research. The insights gained can be used to inform and improve the design of future clinical trials with the collective aim of developing efficacious therapies to support individuals with ASD.
- 11 June 2022
- Published by Springer Nature in Molecular Autism
- Vol. 13 (1) , 1-11
Open AccessLarge multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program
Background: Autism spectrum disorder (ASD) is a common and heterogeneous neurodevelopmental condition that is characterized by the core symptoms of social communication difficulties and restricted and repetitive behaviors. At present, there is an unmet medical need for therapies to ameliorate these core symptoms in order to improve quality of life of autistic individuals. However, several challenges are currently faced by the ASD community relating to the development of pharmacotherapies, namely in the conduct of clinical trials. Balovaptan is a V1a receptor antagonist that has been investigated to improve social communication difficulties in individuals with ASD. In this viewpoint, we draw upon our recent first-hand experiences of the balovaptan clinical development program to describe current challenges of ASD trials. Discussion points: The balovaptan trials were conducted in a wide age range of individuals with ASD with the added complexities associated with international trials. When summarizing all three randomized trials of balovaptan, a placebo response was observed across several outcome measures. Placebo response was predicted by greater baseline symptom severity, online recruitment of participants, and less experienced or non-academic trial sites. We also highlight challenges relating to selection of outcome measures in ASD, the impact of baseline characteristics, and the role of expectation bias in influencing trial results. Conclusion: Taken together, the balovaptan clinical development program has advanced our understanding of the key challenges facing ASD treatment research. The insights gained can be used to inform and improve the design of future clinical trials with the collective aim of developing efficacious therapies to support individuals with ASD.
- Top Cited Papers
- 14 October 2021
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 385 (16) , 1462-1473
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Experimental studies and small clinical trials have suggested that treatment with intranasal oxytocin may reduce social impairment in persons with autism spectrum disorder. Oxytocin has been administered in clinical practice to many children with autism spectrum disorder. We conducted a 24-week, placebo-controlled phase 2 trial of intranasal oxytocin therapy in children and adolescents 3 to 17 years of age with autism spectrum disorder. Participants were randomly assigned in a 1:1 ratio, with stratification according to age and verbal fluency, to receive oxytocin or placebo, administered intranasally, with a total target dose of 48 international units daily. The primary outcome was the least-squares mean change from baseline on the Aberrant Behavior Checklist modified Social Withdrawal subscale (ABC-mSW), which includes 13 items (scores range from 0 to 39, with higher scores indicating less social interaction). Secondary outcomes included two additional measures of social function and an abbreviated measure of IQ. Of the 355 children and adolescents who underwent screening, 290 were enrolled. A total of 146 participants were assigned to the oxytocin group and 144 to the placebo group; 139 and 138 participants, respectively, completed both the baseline and at least one postbaseline ABC-mSW assessments and were included in the modified intention-to-treat analyses. The least-squares mean change from baseline in the ABC-mSW score (primary outcome) was −3.7 in the oxytocin group and −3.5 in the placebo group (least-squares mean difference, −0.2; 95% confidence interval, −1.5 to 1.0; P=0.61). Secondary outcomes generally did not differ between the trial groups. The incidence and severity of adverse events were similar in the two groups. This placebo-controlled trial of intranasal oxytocin therapy in children and adolescents with autism spectrum disorder showed no significant between-group differences in the least-squares mean change from baseline on measures of social or cognitive functioning over a period of 24 weeks. (Funded by the National Institute of Child Health and Human Development; SOARS-B ClinicalTrials.gov number, NCT01944046.)
- 14 October 2021
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 385 (16) , 1462-1473
Top Cited PapersIntranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
Experimental studies and small clinical trials have suggested that treatment with intranasal oxytocin may reduce social impairment in persons with autism spectrum disorder. Oxytocin has been administered in clinical practice to many children with autism spectrum disorder. We conducted a 24-week, placebo-controlled phase 2 trial of intranasal oxytocin therapy in children and adolescents 3 to 17 years of age with autism spectrum disorder. Participants were randomly assigned in a 1:1 ratio, with stratification according to age and verbal fluency, to receive oxytocin or placebo, administered intranasally, with a total target dose of 48 international units daily. The primary outcome was the least-squares mean change from baseline on the Aberrant Behavior Checklist modified Social Withdrawal subscale (ABC-mSW), which includes 13 items (scores range from 0 to 39, with higher scores indicating less social interaction). Secondary outcomes included two additional measures of social function and an abbreviated measure of IQ. Of the 355 children and adolescents who underwent screening, 290 were enrolled. A total of 146 participants were assigned to the oxytocin group and 144 to the placebo group; 139 and 138 participants, respectively, completed both the baseline and at least one postbaseline ABC-mSW assessments and were included in the modified intention-to-treat analyses. The least-squares mean change from baseline in the ABC-mSW score (primary outcome) was −3.7 in the oxytocin group and −3.5 in the placebo group (least-squares mean difference, −0.2; 95% confidence interval, −1.5 to 1.0; P=0.61). Secondary outcomes generally did not differ between the trial groups. The incidence and severity of adverse events were similar in the two groups. This placebo-controlled trial of intranasal oxytocin therapy in children and adolescents with autism spectrum disorder showed no significant between-group differences in the least-squares mean change from baseline on measures of social or cognitive functioning over a period of 24 weeks. (Funded by the National Institute of Child Health and Human Development; SOARS-B ClinicalTrials.gov number, NCT01944046.)
- 1 October 2021
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 60 (10) , S162
6.14 Randomized, Placebo-Controlled Trial With Open-Label Extension of Intranasal Oxytocin for Autism Spectrum Disorder
- 1 October 2021
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 60 (10) , S162
6.14 Randomized, Placebo-Controlled Trial With Open-Label Extension of Intranasal Oxytocin for Autism Spectrum Disorder
- Open Access
- 1 January 2021
- Published by Elsevier in The Journal of Pediatrics: X
- Vol. 7, 100074
Healthy-Weight Kindergarten Children with Autism Spectrum Disorder May Become Overweight and Obese during the First Few Years of Elementary School
- 1 January 2021
- Published by Elsevier in The Journal of Pediatrics: X
- Vol. 7, 100074
Open AccessHealthy-Weight Kindergarten Children with Autism Spectrum Disorder May Become Overweight and Obese during the First Few Years of Elementary School
- 1 October 2020
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 59 (10) , S119-S120
BUILDING PROGRAMS THAT INCREASE ACCESS TO MENTAL HEALTH CARE FOR CHILDREN AND YOUTH, WHILE EXPANDING THE EVIDENCE BASE TO ENHANCE ACCESS AND IMPROVE DIAGNOSIS AND TREATMENT
- 1 October 2020
- Published by Elsevier in Journal of the American Academy of Child & Adolescent Psychiatry
- Vol. 59 (10) , S119-S120
BUILDING PROGRAMS THAT INCREASE ACCESS TO MENTAL HEALTH CARE FOR CHILDREN AND YOUTH, WHILE EXPANDING THE EVIDENCE BASE TO ENHANCE ACCESS AND IMPROVE DIAGNOSIS AND TREATMENT
- Open Access
The Autism Biomarkers Consortium for Clinical Trials (ABC-CT): Scientific Context, Study Design, and Progress towards Biomarker Qualification
Clinical research in neurodevelopmental disorders remains reliant upon clinician and caregiver measures. Limitations of these approaches indicate a need for objective, quantitative, and reliable biomarkers to advance clinical research. Extant research suggests the potential utility of multiple candidate biomarkers; however, effective application of these markers in trials requires additional understanding of replicability, individual differences, and intra-individual stability over time. The Autism Biomarkers Consortium for Clinical Trials (ABC-CT) is a multi-site study designed to investigate a battery of electrophysiological (EEG) and eye-tracking (ET) indices as candidate biomarkers for autism spectrum disorder (ASD). The study complements published biomarker research through: inclusion of large, deeply phenotyped cohorts of children with autism spectrum disorder (ASD) and typical development; a longitudinal design; a focus on well-evidenced candidate biomarkers harmonized with an independent sample; high levels of clinical, regulatory, technical, and statistical rigor; adoption of a governance structure incorporating diverse expertise in the ASD biomarker discovery and qualification process; prioritization of open science, including creation of a repository containing biomarker, clinical, and genetic data; and use of economical and scalable technologies that are applicable in developmental populations and those with special needs. The ABC-CT approach has yielded encouraging results, with one measure accepted into the FDA’s Biomarker Qualification Program to date. Through these advances, the ABC-CT and other biomarker studies in progress hold promise to deliver novel tools to improve clinical trials research in ASD.
Open AccessThe Autism Biomarkers Consortium for Clinical Trials (ABC-CT): Scientific Context, Study Design, and Progress towards Biomarker Qualification
Clinical research in neurodevelopmental disorders remains reliant upon clinician and caregiver measures. Limitations of these approaches indicate a need for objective, quantitative, and reliable biomarkers to advance clinical research. Extant research suggests the potential utility of multiple candidate biomarkers; however, effective application of these markers in trials requires additional understanding of replicability, individual differences, and intra-individual stability over time. The Autism Biomarkers Consortium for Clinical Trials (ABC-CT) is a multi-site study designed to investigate a battery of electrophysiological (EEG) and eye-tracking (ET) indices as candidate biomarkers for autism spectrum disorder (ASD). The study complements published biomarker research through: inclusion of large, deeply phenotyped cohorts of children with autism spectrum disorder (ASD) and typical development; a longitudinal design; a focus on well-evidenced candidate biomarkers harmonized with an independent sample; high levels of clinical, regulatory, technical, and statistical rigor; adoption of a governance structure incorporating diverse expertise in the ASD biomarker discovery and qualification process; prioritization of open science, including creation of a repository containing biomarker, clinical, and genetic data; and use of economical and scalable technologies that are applicable in developmental populations and those with special needs. The ABC-CT approach has yielded encouraging results, with one measure accepted into the FDA’s Biomarker Qualification Program to date. Through these advances, the ABC-CT and other biomarker studies in progress hold promise to deliver novel tools to improve clinical trials research in ASD.
- 1 January 2019
- Published by Elsevier in Disability and Health Journal
- Vol. 12 (1) , 126-130
Parental concern regarding obesity in children with autism spectrum disorder in the United States: National Survey of Children's Health 2016
- 1 January 2019
- Published by Elsevier in Disability and Health Journal
- Vol. 12 (1) , 126-130
Parental concern regarding obesity in children with autism spectrum disorder in the United States: National Survey of Children's Health 2016